Q1 Earnings Forecast for PHIO Issued By HC Wainwright

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Phio Pharmaceuticals in a research note issued on Friday, March 6th. HC Wainwright analyst M. Keller forecasts that the company will earn ($0.24) per share for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.19.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Stock Up 4.3%

Shares of PHIO stock opened at $1.21 on Monday. The firm has a 50 day moving average of $1.12 and a two-hundred day moving average of $1.54. The stock has a market capitalization of $14.06 million, a PE ratio of -0.83 and a beta of 0.90. Phio Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $4.19.

Institutional Investors Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC lifted its position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,694 shares of the company’s stock after purchasing an additional 16,108 shares during the period. Geode Capital Management LLC owned about 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent reporting period. 57.31% of the stock is currently owned by institutional investors and hedge funds.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.